HOOKIPA appoints Katia Schlienger as CMO and Malte Peters to board effective Jan 1, 2023

HOOKIPA Pharma Inc.

Katia Schlienger promoted to CMO effective Jan 1, 2023; previously EVP Clinical R&D since July 2022.
Malte Peters appointed to Board of Directors effective Jan 1, 2023; retiring as MorphoSys Chief R&D Officer at end of 2022.
Schlienger spent 14 years at Merck & Co. in oncology and vaccine development.
Peters previously held leadership roles at Novartis Oncology, Sandoz, and Micromet; also on Tango Therapeutics board.
Peters receives initial option for 19,200 shares, $40k annual cash retainer, and stock awards per non-employee director policy.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Malte Peters

Director

HOOK · HOOKIPA Pharma Inc.

Effective: 2023-01-01
Filed: December 15, 2022, 6:59 PM ET

On December 9, 2022, the Board of Directors (the “Board”) of HOOKIPA Pharma Inc. (the Company”) appointed Malte Peters, M.D. as a director of the Board, effective January 1, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Malte Peters was appointed as Director at HOOKIPA Pharma Inc..

Action: appointed
Role: Director

Exact text from the filing

On December 9, 2022, the Board of Directors (the “Board”) of HOOKIPA Pharma Inc. (the Company”) appointed Malte Peters, M.D. as a director of the Board, effective January 1, 2023.

View on SEC.gov

HOOKIPA Pharma Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-127337

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.